ARDIZZOIA ANTONIO

Ruolo:
Docente a contratto

Pubblicazioni

  • Villa, F., Crippa, A., Pelizzoni, D., Ardizzoia, A., Scartabellati, G., Corbetta, C., et al. (2023). Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(19) [10.3390/ijms241914427]. Dettaglio

  • Soatti, C., Delishaj, D., D'Amico, R., Frigerio, C., Fumagalli, I., Bonsignore, F., et al. (2021). High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses - 14 years of single-centre experience. JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 12(6), 533-539 [10.5114/JCB.2020.101685]. Dettaglio

  • Sala, L., Cirillo, G., Riva, G., Romano, G., Giussani, C., Cialdella, A., et al. (2019). Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype. FRONTIERS IN MOLECULAR NEUROSCIENCE, 12 [10.3389/fnmol.2019.00002]. Dettaglio

  • Ballabio, S., Craparotta, I., Paracchini, L., Mannarino, L., Corso, S., Pezzotta, M., et al. (2019). Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3. INTERNATIONAL JOURNAL OF CANCER, 145(10), 2670-2681 [10.1002/ijc.32288]. Dettaglio

  • De Placido, S., Gallo, C., De Laurentiis, M., Bisagni, G., Arpino, G., Sarobba, M., et al. (2018). Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. THE LANCET ONCOLOGY, 19(4), 474-485 [10.1016/S1470-2045(18)30116-5]. Dettaglio